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Peptide Antigen Treatment of Naive
and Virus-Immune Mice: Antigen-Specific
Tolerance Versus Immunopathology
Peter Aichele,* Karin Brduscha-Riem,* Thus, although autoreactive T cells arepresent innormal
individuals (Schluesener and Wekerle, 1985; Pette et al.,Stephan Oehen,* Bernhard Odermatt,²
Rolf M. Zinkernagel,* Hans Hengartner,* 1990; Aichele et al., 1996), they are harmless as long as
the self-antigen is not presented by professional anti-and Hanspeter Pircher³
* Institute of Experimental Immunology gen-presenting cells in lymphoid tissues. However, ge-
netic predisposition, injuries, or exposure to cross-reac-Department of Pathology
²Department of Pathology tive antigens may activate these T cells and cause
autoimmune diseases (Londei et al., 1985; Sinha et al.,University of ZuÈ rich
CH-8091 ZuÈ rich 1990; Wucherpfennig and Strominger, 1995).
In such instances, it would be desirable to manipu-Switzerland
late the immune system in an antigen-specific manner
by specifically down-regulating autoreactive or graft-
rejecting T cells without affecting other cells of the im-Summary
mune system. To achieve T cell tolerance as a therapeu-
tic goal, it is essential to identify the antigens recognizedPeptide-specific down-regulation of T cell responses
by the disease-mediating T cells (RoÈ tzschke et al., 1990;may represent a powerful tool to intervene in autoim-
Jardetzky et al., 1991; Rudensky et al., 1991; Ram-mune diseases or graft rejections. It is therefore im-
mensee et al., 1993a, 1993b) and to define protocols forportant to know whether peptide treatment tolerizes
antigen application that specifically tolerize naive as wellboth naive and antigen-experienced memory T lym-
as antigen-experienced T cells.phocytes. Here we show that a major histocompatibil-
Numerous reports have shown that it is possible toity complex class I binding peptide, derived from the
tolerize naive CD41 T cells in vivo (Dresser, 1962; Mitchi-glycoprotein (GP33 peptide) of lymphocytic chorio-
son, 1964; Rajewsky and Brenig, 1974; Oki and Sercarz,meningitis virus (LCMV), specifically tolerized naive
1985; Ria et al.,1990; Burstein and Abbas, 1993; Romballcytotoxic T lymphocytes (CTL) when administered
and Weigle, 1993; Kearney et al., 1994; Vidard et al.,three times intraperitoneally in incomplete Freund's
1994; Chen et al., 1995) and hence to prevent the devel-adjuvants. However, in the presence of GP33-specific
opment of autoimmune responses or allergic reactionsmemory CTL in LCMV-primed mice, the same treat-
in various animal models (Wraith et al., 1989; Hoyne etment had a general immunosuppressive effect on un-
al., 1993; Kaufman et al., 1993; Metzler and Wraith, 1993;related third-party antigen-specific T cell responses
Miller et al., 1991; Tisch et al., 1993; Weiner et al., 1994).and caused severe immunopathological damage to
Peptide-specific immunotherapy in an ongoing diseasethe spleen.
by down-regulation of activated CD41 T cells has so far
succeeded only in the murine model of experimental
autoimmune encephalomyelitis (Smilek et al.,1991; GaurIntroduction
et al., 1992). Recent studies have shown that repetitive,
systemic administration of peptides results in peripheralThe function of the immune system is to eliminate foreign
deletion of naive CD81 cytotoxic T lymphocytes (CTL)pathogens while maintaining unresponsiveness against
in vivo (Kyburz et al., 1993; Mamalaki et al., 1993; Aicheleself-antigens. T cell tolerance is achieved by both thymic
et al., 1995) and can prevent a virus-induced T cell-and peripheral processes. Thymocytes reactive for self-
mediated autoimmune diabetes in a transgenic mousepeptides are eliminated by clonal deletion (Kappler et
model (Aichele et al., 1994). However, the question ofal., 1987; Kappler et al., 1988; Kisielow et al., 1988; Mac-
whether antigen-experienced, memory CD81 T lympho-Donald et al., 1988; Sha et al., 1988; Pircher et al., 1989)
cytes can be tolerized with peptide antigens in vivo hasor are functionally inactivated (Blackman et al., 1990;
not yet been addressed.Roberts et al., 1990; Ramsdell et al., 1989). However,
We therefore have used a major histocompatibilitycentral tolerance is incomplete because of the absence
complex class I (Db) binding peptide derived from theof particular self-peptides in the thymus. Therefore, po-
glycoprotein GP33±41 (GP33 peptide) of lymphocytictentially autoreactive T cells will reach the periphery,
choriomeningitis virus (LCMV) as a model antigen, towhere they may be tolerized by several mechanisms
study whether antigen-experienced, memory CD81 Tupon exposure to their specific antigen (Burkly et al.,
lymphocytes are also susceptible to peptide-induced1989; Rammensee et al., 1989; Rocha and von Boehmer,
tolerance.1991; Miller and Morahan, 1992; HaÈ mmerling et al.,
1993). T cell tolerance is not established toward self-
antigens located in immunologically sequestered sites Results
(Ohashi et al., 1991; Oldstone et al., 1991) or to those
expressed below a critical concentration level (Schild Peptide Treatment of Naive and of LCMV-Primed
et al., 1990; Ferber et al., 1994; Oehen et al., 1994). Mice to Induce T Cell Tolerance
The effect of LCMV GP33 peptide treatment on naive
and LCMV-primed CTL was compared using a protocol³Present address: Institute of Med. Microbiology and Hygiene, Uni-
versity of Freiburg, D-79104 Freiburg, Germany. for peptide administration that has been established
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Figure 1. Peptide Treatment of Naive and LCMV-Primed Mice
In the first group, unprimed C57BL/6 mice (A±C) were treated intra-
peritoneally three times in 3-day intervals with IFA (open circles) or
500 mg GP33 peptide in IFA (closed circles). Five days after the last
peptide treatment the mice were infected intravenously with 200
pfu LCMV-WE, and 30 days later spleen cells of these mice were
restimulated in vitro for 5 days with irradiated LCMV-infected perito-
neal macrophages. In the second group, LCMV-primed mice (day
30 after LCMV infection) (D±F) were injected intraperitoneally three
times in 3-day intervals with IFA (open circles) or with 500 mg GP33
peptide in IFA (closed circles). Five days after the last peptide appli-
cation, spleen cells of these mice were restimulated in vitro for
5 days with irradiated LCMV-infected peritoneal macrophages as
Figure 2. Immunosuppressive Effect of Peptide Treatment on Unre-described in Experimental Procedures. CTL activities of effector
lated Memory CTL Responsescells from both groups were tested on GP33-loaded (A and D),
VSV-primed mice (A) and mice primed for both VSV and LCMV (B)NP394-loaded (B and E), or unloaded (C and F) MC57G target cells
were injected intraperitoneally three times at 3-day intervals withat the indicated dilutions.
either 500 mg LCMV GP33 peptide in IFA (A and B, left) or IFA alone
(A and B, right). Five days after the last peptide treatment the spleen
previously to tolerize naive CTL in vivo (Aichele et al., cells were restimulated in vitro for 5 days with the VSV nucleoprotein
1995). Unprimed C57BL/6 mice (Figures 1A±1C) were expressing cell line N1 and tested for VSV-specific killing in a 51Cr
treated three times at 3-day intervals with 500 mg of release assay on unloaded (open circles) or VSV NP52-loaded
(closed circles) EL-4 target cells. LCMV-primed mice (C) and miceGP33 peptide in incomplete Freund's adjuvants (IFA)
primed for both VSV and LCMV (D) were treated three times in 3-dayintraperitoneally. Five days after the last peptide treat-
intervals with either 500 mg of VSV NP52 peptide in IFA (C and D,ment, mice were infected with LCMV to expand LCMV-
left) intraperitoneally or IFA alone (C and D, right). Spleen cells fromspecific CTL efficiently invivo. Thirtydays after infection,
these mice were restimulated in vitro for 5 days with LCMV-infected
spleen cells from these mice were restimulated in vitro peritoneal macrophages and tested then for LCMV-specific cytoly-
with LCMV-infected macrophages, and LCMV-specific sis on unloaded (opentriangles) or LCMV GP33-loaded (closed trian-
CTL activities were determined. Control mice, pre- gles) EL-4 target cells.
treated with IFA alone, exhibited high CTL activities
against both GP33 peptide±loaded and NP394±408
induced an immunosuppression, since the LCMV GP33-(NP394 peptide)±loaded target cells (Figures 1A and 1B,
specific and NP394-specific CTL responses were equallyopen circles). In contrast, GP33 peptide±treated mice
abrogated. Therefore, GP33 peptide treatment of virus-were unable to generate GP33-specific CTL activities,
primed mice caused an immunosuppression rather thanwhile the CTL response against NP394 peptide±loaded
an antigen-specific unresponsiveness or tolerance.target cells was within the normal range (Figures 1A and
1B, closed circles). Thus, GP33 peptide treatment toler-
Analysis of Immune Suppression after Peptideized naive CTL in vivo in an antigen-specific manner.
Treatment of Specific Memory CTLTo examine whether GP33-specific memory CTL
To examine whether treatment of memory CTL with spe-could be similarly tolerized, mice primed 30 days pre-
cific peptide antigen suppresses not only CTL re-viously with LCMV were treated with GP33 peptide in
sponses to the same virus but also unrelated third-partyIFA as described above (Figures 1D±1F). Spleen cells
antigen-specific CTL responses, mice primed for bothfrom these mice were restimulated in vitro, and LCMV-
vesicular stomatitis virus (VSV) and LCMV were treatedspecific CTL activities were determined. The analysis of
with the LCMV GP33 peptide, and the effect of thisCTL responses specific for GP33 or NP394 epitopes
treatment on the VSV-specific CTL response was ana-revealed that both were strongly reduced in LCMV-
lyzed. VSV-primed mice treated with LCMV GP33 pep-primed mice after treatment with the GP33 peptide
tide (Figure 2A, left) generated VSV NP52±59 (NP52 pep-(Figures 1D and 1E, closed circles), whereas they were
tide)±specific CTL responses comparable to those ofunimpaired in LCMV-primed control mice treated with
VSV-primed mice treated with IFA alone (Figure 2A,IFA alone (Figures 1D and 1E, open circles). Thus, while
right), indicating that LCMV GP33 peptide treatment it-naive CTL were efficiently rendered tolerant, GP33 pep-
tide treatment of memory CTL in LCMV-primed mice self was neither immunosuppressive nor toxic. However,
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Figure 3. Immunohistological Analysis of
Spleen Sections from Naive and LCMV-
Primed Mice Treated with LCMV GP33
Peptide
Naive and LCMV-primed C57BL/6 mice were
treated intraperitoneally three times at 3-day
intervals with 500 mg of GP33 peptide in IFA.
Three days after the last peptide treatment,
spleens were removed, snap-frozen in liquid
nitrogen, and cut into 5 mm sections. Spleen
sections from GP33 peptide±treated naive (A,
C, and E) and LCMV-primed mice (B, D, and
F) were stained with monoclonal antibodies
specific for B220 (A and B), CD4 (C and D),
and CD8 (E and F). Metallophilic marginal
zone macrophages were already stained with
monoclonal antibody MOMA-1 after the first
application of GP33 peptide (G and H).
when mice primed with bothVSV and LCMV were treated while IFA treatment alone did not affect the LCMV-spe-
cific CTL response (Figure 2D, right). In contrast, micewith LCMV GP33 peptide, the VSV-specific CTL re-
sponse was completely abrogated (Figure2B, left), while primed with LCMV only, when treated with VSV NP52
peptide, mounted a normal LCMV-specific CTL re-control IFA-treated VSV/LCMVmemory mice had normal
VSV-specific CTL activities (Figure 2B, right). Thus, only sponse against target cells loaded with LCMV GP33
peptide (Figure 2C, left). These findings confirm thatin the presence of LCMV-specific memory CTL did the
application of LCMV GP33 peptide exhibit a nonspecific only in the presence of the specific memory CTL popula-
tion did administration of the corresponding peptideimmunosuppressive effect on unrelated third-party anti-
gen-specific CTL responses. antigen lead to nonspecific suppression of unrelated
CTL responses in vivo.To test whether this phenomenon was unique for the
LCMV GP33 peptide treatment, mice primed with both
VSV and LCMV were treated intraperitoneally three LCMV GP33 Peptide Treatment of LCMV-Primed
Mice Induced Severe Immunopathologytimes with the VSV NP52 peptide, and LCMV-specific
CTL activities were examined. Miceprimed with VSV and in the Spleen
To investigate the possible mechanisms underlying theLCMV failed to generate LCMV-specific CTL activities
when treated with VSV NP52 peptide (Figure 2D, left), observed immunosuppression, frozen sections of spleens
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Figure 4. Activation of GP33-Specific Mem-
ory CTL after a Single Peptide Injection and
In Vivo Loading of Spleen Cells and Peritoneal
Macrophages with Peptide
LCMV-primed mice (30±50 days after infec-
tion) were treated intravenously with 500 mg
of GP33 peptide in HBSS (A) or left untreated
(B). Twenty-four hours later the ex vivo CTL
activity of splenocytes was tested on GP33-
loaded (closed circles) or unloaded (open cir-
cles) EL-4 target cells at the indicated ef-
fector- to- target ratios in a 5 hr standard 51Cr
release assay.
(C) Splenocytes of GP33 peptide±treated
(closed bar) or untreated (open bar) LCMV-primed mice were irradiated (3000 rad) and used as stimulators for GP33-specific responder CTL
in a proliferation assay.
(D) Peritoneal macrophages of C57BL/6 mice treated intraperitoneally either with 500 mg of GP33 peptide in IFA (closed circles) or with IFA
alone (open circles) were removed 24 hr later and used as target cells in a 51Cr release assay. In vivo sensitization of peritoneal macrophages
with peptide was assessed with splenocytes of acutely LCMV-infected mice as effector cells.
from naive and LCMV-primedmice that had beentreated some cases after the first peptide application (Figures
3G and 3H). Thus, peptide treatment of specific memorythree times with GP33 peptide intraperitoneally ac-
cording to the standard protocol were stained with CTL induced severe immunopathological damage to the
spleen. This finding may well explain the observed sup-monoclonal antibodies for B220, CD4, and CD8 (Figure
3). Unprimed mice treated with GP33 peptide exhibited pressive effect on unrelated, third-party antigen-specific
CTL responses.normal splenic architecture: the white pulp contained
distinct primary B cell follicles, germinal centers, mar-
ginal zone B lymphocytes, and T cell±rich periarteriolar GP33-Specific Memory CTL Are Activated
after a Single Injection of Peptidelymphoid sheaths (Figures 3A, 3C, and 3E). In striking
contrast, evaluation of spleen sections from LCMV- To provide further evidence that the peptide-induced
immunopathology was caused by GP33-specific mem-primed mice treated with GP33 peptide revealed exten-
sive destruction of lymphoid follicle structures. The size ory CTL, LCMV-primed mice were treated once with
GP33 peptide (Figure 4A) or were left untreated (Figureand number of B cell follicles was partially reduced (Fig-
ure 3B), and the T cell±rich region of the periarteriolar 4B). After 24 hr, the GP33-specific ex vivo CTL activities
of splenocytes were assayed in a 5 hr standard 51Crlymphoid sheaths was undefinable. The remaining CD41
and CD81 T lymphocytes were randomly distributed release assay on GP33-loaded (closed symbols) or un-
loaded (open symbols) EL-4 target cells. Spleen cellsthroughout the whole organ (Figures 3D and 3F). Histo-
logical analysis of different splenic antigen±presenting from untreated LCMV-primed mice exhibited a low level
of GP33 peptide±specific CTL activity ex vivo (Figurecells revealed that the metallophilic marginal zone mac-
rophages (stained with monoclonal antibody MOMA-1) 4B), whereas LCMV-primed mice treated with GP33
peptide generated strong GP33-specific CTL responseswere absent in LCMV-primed mice after GP33 peptide
treatment, whereas the dendritic cell populations (Figure 4A) when assayed within 24 hr after peptide
treatment.(stained with monoclonal antibody N418) were only
slightly reduced, when compared with GP33 peptide± To evaluate the efficiency of peptide loading in vivo
after peptide injection, the same spleen cells from pep-treated naive mice (data not shown). Metallophilic mar-
ginal zone macrophages had already disappeared in tide-treated LCMV-primed mice were used as stimulator
Figure 5. Detection of Apoptotic Cells in Spleens from Peptide-Treated LCMV-Primed Mice
Naive (A) and LCMV-primed (B) C57BL/6 mice were treated once with 500 mg of GP33 peptide and killed after 14 hr, and the spleens were
snap frozen in liquid nitrogen. Five-micron spleen sections were stained for apoptotic cells with the TUNEL assay as described in Experimental
Procedures. Spleen sections from untreated LCMV-primed mice were used as negative controls (C).
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cells to provoke proliferation of specific T cells in an in
vitro assay (Figure 4C). Responder CTL from transgenic
mice expressing a GP33-specific T cell receptor (TCR)
were strongly stimulated by irradiated spleen cells from
mice injected 24 hr previously with GP33 peptide (Figure
4C, closed bar), but not by spleen cells from untreated
controls (Figure 4C, open bar). To further address the
question of whether peptide administration is sufficient
to sensitize cells in vivo for CTL-mediated lysis, perito-
neal macrophages from peptide treated or untreated
mice were used as target cells in 51Cr release assays.
As shown in Figure 4D, peritoneal macrophages from
GP33 peptide±treated mice were efficiently lysed by
LCMV-specific effector cells, whereas the correspond-
ing macrophage population from untreated mice was
not susceptible to killing.
These results indicate that GP33 peptide treatment
of LCMV-primed mice rapidly activated GP33-specific
memory CTL and simultaneously loaded spleen cells in
vivo with the GP33 peptide. It is tempting to speculate
that these peptide-loaded spleen cells may serve as
target cells in vivo for the GP33 peptide±activated mem-
ory CTL, which may explain the observed immunopa-
thology after GP33 peptide administration in LCMV-
primed mice. To test this hypothesis, frozen sections of
spleens from GP33 peptide±treated, naive, or LCMV-
primed mice were examined for apoptotic cells using the
terminal deoxynucleotidyl transferase (TdT)±mediated
dUTP-biotin nick end labeling (TUNEL) assay. Immuno-
Figure 6. Antigen-Specific and Contact-Dependent Elimination ofhistological analysis of spleen sections from LCMV-
an Indicator Cell Population in LCMV-Primed Miceprimed mice revealed a high number of apoptotic cells
C57BL/6 mice were treated intraperitoneally either with 500 mg12±24 hr after the GP33 peptide administration, mainly
LCMV GP33 peptide or VSV NP52 peptide in IFA for peptide antigen
localized in the lymphoid follicles of the white pulp (Fig- loading of spleen cells in vivo. Fifteen hours after the peptide appli-
ure 5B). In contrast, almost no apoptotic cells could be cation, spleens were removed. Splenocytes from LCMV GP33 pep-
detected in spleen sections from GP33 peptide±treated tide±treated mice were labeled with CFSE at a high concentration,
and spleen cells from VSV NP52 peptide±treated mice were labelednaive mice (Figure 5A), demonstrating that the peptide
with a low CFSE concentration. This resulted in two cell populationstreatment itself is not toxic to spleen cells. Furthermore,
of different CFSE fluorescence intensities. The two cell populationsonly a few apoptotic cells could be found in untreated
were mixed 1:1, and 6 3 107 cells were transferred intravenously
LCMV-primed control mice (Figure 5C). Thus, the high as indicator cells into naive or LCMV-primed mice that had been
number of apoptotic cells in the spleens of LCMV- pretreated intraperitoneally with 500 mg of GP33 peptide in IFA 5
primedmice may bea directconsequence of thepeptide hr before. Lymphocytes from naive (A, C, and E) and LCMV-primed
mice (B, D, and F) were taken 2 and 24 hr after transfer and analyzedapplication, which readily activated the specific memory
by flow cytometry.CTL and in parallel loaded the spleen cells with GP33
peptide, thereby sensitizing them for CTL-mediated
lysis.
The two spleen cell preparations were mixed 1:1 and
then transferred intravenously as indicator cells into na-
ive or LCMV-primed mice that had been pretreated withPeptide-Mediated Immunopathology in
LCMV-Primed Mice Is an Antigen-Specific GP33 peptide 5 hr before transfer. Blood samples of the
recipient mice were taken 2 and 24 hr after adoptiveand Contact-Dependent Process
To evaluate further the mechanism of peptide-induced transfer to follow the fate of peptide-loaded spleen cells
in vivo. Fluorescence-activated cell sorter analysis ofimmunopathology in LCMV-primed mice, the following
experiment was performed. C57BL/6 mice were treated blood samples from naive mice 2 hr after transfer re-
vealed two CFSE-labeled indicator cell populations ofintraperitoneally either with LCMV GP33 peptide or with
VSV NP52 peptide to load splenocytes in vivo with pep- comparable size: VSV NP52 peptide±loaded cells with
a low fluorescence intensity (CFSElo) and LCMV GP33tide. Fifteen hours later, spleens were removed and
splenocytes were labeled in vitro with the vital dye peptide±loaded cells with a high fluorescence intensity
(CFSEhi) (Figure 6A). The two differentially labeled cell5- (and 6-) carboxyfluorescein diacetate succinimidyl
ester (CFSE). Splenocytes from LCMV GP33 peptide± populations were also detectable in blood samples of
LCMV-primed mice 2 hr after transfer; however, thetreated mice were labeled with a high intensity of CFSE
fluorescence, whereas splenocytes from VSV NP52 pep- LCMV GP33 peptide±loaded, CFSEhi cell population was
already reduced in numbers, when compared to the VSVtide were labeled with a low intensity of CFSE fluores-
cence, to allow distinction between the two populations. NP52 peptide±loaded, CFSElo cell population (Figure
Immunity
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circles), while the NP394 peptide±specific CTL re-
sponses were unimpaired (Figure 7A, open circles).
Thus, despite the extremely high GP33 peptide±specific
CTL precursor frequency in TCR transgenic mice, the
GP33 peptide treatment tolerized the naive, GP33-spe-
cific CTL in a highly specific manner without inducing
general immunosuppression. These data indicate that
yet undefined qualitative differences between naive
and memory CTL, rather than the quantitative differ-
ences in precursor frequencies alone, account for the
observed immunopathology in LCMV-primed mice fol-
lowing LCMV GP33 peptide treatment.
Discussion
In the current study, we compared virus-specific naive
and memory CTL for their susceptibility to peptide-
Figure 7. Peptide-Specific Tolerization of Naive CTL in TCR
induced tolerance in vivo. GP33 peptide administeredTransgenic Mice
intraperitoneally three times at 3-day intervals tolerizedTCR transgenic mice were treated intraperitoneally three times at
naive CTL in a highly antigen-specific manner. In con-3-day intervals with 500 mg of GP33 peptide in IFA (A) or with IFA
trast, the same peptide treatment in the presence ofalone (B). Five days after the last peptide treatment the mice were
infected intravenously with 2 3 104 pfu LCMV-WE, and ex vivo CTL GP33-specific memory CTL in LCMV-primed mice in-
activities of splenocytes were assayed 8 days later in a 51Cr release duced severe immunopathological destruction in the
assay. EL-4 target cells were either loaded with GP33 peptide spleen, accompanied by a nonspecific immunosuppres-
(closed circles) or with NP394 peptide (open circles).
sion rather than antigen-specific tolerance.
Several mechanisms may account for the specific tol-
erance induction of naive CD81 T lymphocytes after
6B). This reduction was even more pronounced 24 hr repetitive and systemic peptide application. CTL may
after transfer of labeled cells into LCMV-primed mice. At be tolerized because of the lack of specific TH cells
this time the LCMV GP33-loaded, CFSEhi cell population (Guerder and Matzinger, 1992) or because they are trig-
was completely absent, while the VSV NP52 peptide± gered mainly by nonprofessional antigen-presenting
loaded, CFSElo cell population was virtually unchanged cells and therefore will not receive the appropriate costi-
(Figure 6D). In contrast, blood samples from naive mice mulation required for clonal expansion (Schwartz, 1990;
24 hr after transfer exhibited both peptide-loaded cell Gimmi et al., 1991; Linsley et al., 1991; Matzinger, 1994)
populations of comparable sizes (Figure 6C). The same and for the activation of the cytolytic machinery (Azuma
result was obtained when splenocytes were analyzed et al., 1992; Guerder et al., 1995; Lanier et al., 1995).
24 hr after transfer (Figures 6E and 6F). These results This view correlates well with the observation that T
demonstrate that GP33 peptide±induced immunopa- cells are transiently activated during tolerance induction
thology and immunosuppression in LCMV-primed mice but never gain full effector function (Kyburz et al., 1993;
is an antigen-specific, contact-dependent mechanism Mamalaki et al., 1993; Kearney et al., 1994; Vidard et al.,
and therefore most likely not mediated by cytokines. 1994). Furthermore, systemic application of high doses
of peptide may trigger virtually all potentially available
Lack of GP33 Peptide±Induced Immune specific CTL, rather than only a fraction as is usually
Suppression in Naive Transgenic Mice the case after a local initiation of an infection. These
Expressing a GP33-Specific TCR CTL become terminally differentiated and will die within
Virus-primed memory mice have a 100- to 1000-fold a few days, as has been demonstrated for superantigens
higher CTL precursor frequency when compared to na- and rapidly replicating viruses (Webb et al., 1990;
ive mice. This may explain the GP33 peptide±induced Moskophidis et al., 1993). In addition, CTL may undergo
immunosuppression in LCMV-primed mice. To deter- activation-induced cell death upon reencountering anti-
mine whether this quantitative aspect accounted for the gen during the cell cycle (Lenardo, 1991; Critchfield et
different outcome of peptide treatment in unprimed and al., 1994; Zheng et al., 1995).
LCMV-primed mice, transgenic mice expressing a GP33 Are memory CTL more resistant to these antigen-
peptide±specific TCR on 50% of all CD81 T cells were driven tolerance mechanisms? To answer this question,
used. TCR transgenic mice were treated three times at quantitative and qualitative aspects of CTL responses
3-day intervals intraperitoneally with 500 mg of GP33 have to be compared in unprimed and virus-primed
peptide in IFA and then were infected with LCMV. Splen- mice. Virus-primed mice exhibit a 100- to 1000-fold
ocytes of these mice were assayed for CTL activities higher virus antigen-specific CTL precursor frequency
8 days later. IFA-treated TCR transgenic control mice (Moskophidis et al., 1987) when compared to unprimed
exhibited potent CTL activities against both GP33 pep- mice. However, the increased precursor frequency
tide± (Figure 7B, closed circles) and NP394 peptide± alone cannot account for the observed immunosuppres-
loaded target cells (Figure 7B, open circles). In contrast, sion in LCMV-primed mice, since GP33 peptide treat-
TCR transgenic mice treated with GP33 peptide failed to ment of TCR-transgenic mice expressing a GP33-spe-
cific TCR on more than 50% of the CD81 T cells tolerizedgenerate GP33-specific CTL activities (Figure 7A, closed
Tolerance or Immunopathology by Peptide Treatment
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the naive GP33-specific CTL completely, without affect- loaded in vivo with either LCMV GP33 peptide or with
VSV NP52 peptide as indicator cell populations, re-ing the LCMV NP394 peptide±specific CTL response.
Thus, qualitative differences between naive and memory vealed that after adoptive transfer into LCMV-primed
mice only the GP33 peptide±loaded cell population wasCTL appeared to be more crucial for explaining the dif-
ferent outcomes of the peptide treatment. These results eliminated by the GP33-specific memory CTL, whereas
the VSV NP52 peptide±loaded population was not de-fit well with the finding that male B lymphocytes trans-
ferred into female hostsefficiently tolerized H-Y±specific stroyed. Therefore the immunosuppression and immu-
nopathology, demonstrated in LCMV-primed mice afternaive but not memory CTL (Fuchs and Matzinger, 1992).
Furthermore, our data indicate that memory CTL, in con- treatment with LCMV GP33 peptide, is mediated by an
antigen-specific and contact-dependent mechanismtrast to naive CTL, gain full cytolytic effector function
within 24 hr after peptide treatment, measurable directly rather than by the release of cytokines. This view is
further supported by the finding that splenocytes ofin a standard 51Cr release assay. At this time, peptide
antigen still persists in the spleen and sensitizes virtually LCMV-primed mice treated once with GP33 peptide ex-
hibited the same cytokine pattern as LCMV-primed miceall spleen cells as targets for the activated memory CTL.
Several reports have demonstrated that peptide-loaded challenged with LCMV. Both spleen cell populations
produced interferon-g, whereas interleukin-4 and tumorT cells can serve as targets for activated CTL in vitro
and in vivo (Pemberton et al., 1990; Walden and Eisen, necrosis factor a were not detectable (data not shown).
Experimental adoptive transfer of LCMV-primed1990; Moss et al., 1991; Dutz et al., 1992; Kyburz et al.,
1993). Such a mechanism may explain the extensive spleen cells into congenital virus carriers expressing
antigen over the whole body has revealed peripheraldestruction of lymphoid architecture in the spleen of
peptide-treated memory mice, which is likely to be the deletion of memory CTL (Moskophidis et al., 1993). How-
ever, the virus carrier model is different from the peptidecause of the observed immunosuppression. Although
we changed several parameters of our peptide applica- system studied here, since most lymphocytes are not
infected by LCMV and therefore do not serve as targetstion protocol by varying the dose of antigen, the use of
adjuvants, and the time intervals of application, we were for activated memory CTL (Ahmed et al., 1987). This
may explain why no immunosuppression was observedunable to avoid this peptide-induced immunopathologi-
cal process (data not shown). Therefore the question of in this experimental approach.
So far, peptide-specific immunotherapy of ongoingwhether memory CTL are finally tolerized in our model
remains open since the absence of a GP33-specific CTL diseases and down-regulation of activated CD41 T cells
has been successfully demonstrated only in the experi-response after GP33 peptide treatment of LCMV-primed
mice could be due to tolerance induction or to immuno- mental autoimmune encephalomyelitis model (Smilek et
al., 1991; Gaur et al., 1992). The tolerization of memorysuppression or to both.
Taken together, the data presented suggest that pep- CD41 T cells may be achieved without thecomplications
demonstrated in this study since CD41 T cells normallytide treatment of memory CTL in vivo will activate the
cytolytic machinery before an antigen-specific tolerance do not exhibit cytolytic activities and therefore are less
likely to mediate acute immunopathological damage.status can be achieved. Such a difference in the in vivo
kinetics of CTL activation versus CTL tolerization after Furthermore, since murine T cells do not express MHC
class II molecules, they would not be loaded with classpeptide application may well explain the immunopathol-
ogy and immunosuppression observed. This is con- II-binding peptides to become a direct target for acti-
vated T helper cells.firmed by a recent study showing that high doses of
peptides can induce apoptotic death of CD81 effector T In conclusion, this study shows that peptide treatment
of antigen-primed hosts mayhave deleteriousand unde-lymphocytes in vitro within 40±48 hr. During this period,
cloned CTL exposed to peptide were completely inhib- sirable effects, since specific memory CTL are rapidly
activated and cause severe immunopathology in theited in their proliferative response but not in their cyto-
lytic effector function (Alexander-Miller et al., 1996).Sim- spleen, leading to immunosuppression. For therapeutic
intervention in autoimmune diseases, such a protocolilarly, signaling via the TCR alone in the absence of
interleukin-2 will inhibit proliferation of an antigen-expe- would constitute a risk, because the potentially autore-
active memory CTL are activated and gain full effectorrienced CTL clone in vitro but not block the cytolytic
effector function (Otten and Germain, 1991). function before the death of these cells is induced.
The immunosuppression described in our model is Therefore, other strategies must be developed to over-
different from the bystander suppression of CD41 T lym- come these problems and to render peptide-specific
phocytes observed in certain experimental systems tolerization of memory CTL feasible for antigen-specific
after oral application of antigens. In these cases the intervention in autoimmune diseases and graft rejec-
suppressive effect of antigen application on unrelated tions.
third-party antigen-specific CD41 T lymphocytes ismost
probably mediated by so-called suppressor cells, by the
Experimental Proceduresrelease of transforming growth factor b, or possibly by
a TH1±TH2 shift in the cytokine production (Khoury et al.,
Animals1990; Miller et al., 1992; Miller et al., 1993; Al-Sabbagh
C57BL/6 (H-2b) mice were obtained from the breeding colony of the
et al., 1994; Chen et al.,1995). Immunopathological dam- Institut fuÈ r Zuchthygiene (Tierspital ZuÈ rich, Switzerland). The LCMV
age after antigen application as demonstrated in our TCR transgenic mouse line 318 has been described previously (Ky-
model have not been described in these systems. Exper- burz et al., 1993). Animals were kept under conventional conditions
and used in the experiments 14±24 weeks after birth.iments using differentially CFSE-labeled spleen cells,
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Cell Lines rad) spleen cells (5 3 105 cells/well) as stimulators from GP33 pep-
tide±treated or untreated LCMV memory mice. Forty-eight hoursMC57G (H-2b), a methylcholanthrene-induced fibroblast cell line,
and EL-4 (H-2b), a thymoma cell line, were used as target cells. The later cultures were pulsed with 1 mCi/well of [3H]thymidine for 12±15
hr and then harvested onto filter papers. Results are displayed asN1 cell line is a clone from EL-4 cells transfected with the VSV-IND
nucleoprotein gene under the controlof the Rous sarcoma virus long counts per minute determined in a scintillation counter.
terminal repeat and constitutively expresses the VSV nucleoprotein
(Puddington et al., 1986). Immunohistochemistry
Spleens were immersed in HBSS and snap-frozen in liquid nitrogen,
and 5 mm±thick cryostat sections were cut and fixed in acetone forViruses
10 min. These sections were incubated with the primary antibodiesThe LCMV-WE strain was originally obtained from Dr. F. Lehmann-
YTS.169.4.2 (anti-CD8; 1:6000 diluted) (Cobbold et al., 1984),Grube (Hamburg, Germany) and was propagated in our laboratory
YTS191.1 (anti-CD4; 1:10,000 diluted) (Cobbold et al., 1984), anti-on L929 fibroblast cells (Lehmann-Grube, 1971). Virus stocks were
B220 (1:50 diluted), MOMA-1 (1:50 diluted), or N418 (1:50 diluted)diluted in minimal essential medium supplemented with 2% fetal
for 60 minfollowed by a two-step indirect immunoenzymatic stainingcalf serum (FCS). Mice were infected intravenously with 200 plaque-
with alkaline phosphatase-labeled goat anti-rat immunoglobulinforming units (pfu) of LCMV-WE and used in the experiments 30±60
(TAGO, Burlingame, CA) for 30 min. After washing, an alkaline phos-days later. VSV-IND (VSV Indiana, Mudd-Summer isolate) seeds,
phatase-labeled donkey anti-goat immunoglobulin (Jackson Immu-originally obtained from Dr. D. Kolakofsky (Geneva, Switzerland),
noresearch, PA) was used for an additional 30 min. Antibody dilu-were grown on BHK 21 cells and plagued on Vero cells (McCaren
tions were prepared in 0.1 M Tris-HCl (pH 7.4) containing 5% normalet al., 1959; Charan and Zinkernagel, 1986). Mice were infected
mouse serum. Alkaline phosphatase was detected by a red colorintravenously with 2 3 106 pfu of VSV-IND and used 30±60 days
reaction by incubating with naphthol A-BI phosphate and with Newlater. To generate memory responses against both viruses, mice
Fuchsin for 15 min. Sections were counterstained with Mayer's he-were first injected with LCMV-WE and 30 days later with VSV-IND
malum for 5 min.at the doses described above.
For the TUNEL assay, frozen sections were dried for 48 hr at 48C
and fixed with 2% paraformaldehyde for 15 min at room tempera-
Peptide Treatment
ture. After washing with 50 mM Tris buffer (pH 7.5), the sections
LCMV glycoprotein peptide GP33±41 (KAVYNFATM) (Pircher et al.,
were first incubated for 15 min with Tris buffer containing 0.05 M
1990), LCMV nucleoprotein peptide NP394±408 (AIFQPQNGQFI
glycine and then for 2 min with a solution of 0.1% sodium citrate
HFYR) (Schulz et al., 1989), and VSV nucleoprotein NP52±59 (RGYV
and 0.1% Triton X-100 at 48C. The sections were washed with TrisYQGL) (van Bleek and Nathenson, 1990) were synthesized by the
buffer, immersed in TdT buffer (Promega), and then incubated forsolid-phase method and purchased from Neosystem Laboratoire
1 hr with the reaction mixture containing digoxigenin-dUTP and TdT(Strasbourg, France). For technical reasons (to prevent dimer forma-
according to the manufacturer's instructions. Sections were washedtion), the original cysteine at the anchor position 41 in the LCMV
with Tris buffer, blocked for 15 min with Tris buffer containing 2%glycoprotein peptide GP33±41 was replaced by methionine. For
FCS, incubated for 1 hr with a alkaline phosphatase±labeled anti-injections, peptides were dissolved in Hanks' balanced salt solution
digoxigenin immunglobulin (1:800 diluted in Tris buffer; Boehringer(HBSS), emulsified 1:1 (vol/vol) in IFA (Difco Laboratories, Detroit,
Mannheim, Germany), washed with Tris buffer, and developed forMI), and injected intraperitoneally at 3-day intervals at the indicated
7 min with naphthol A-BI phosphate and with New Fuchsin. Sectionsdoses in a total volume of 200 ml.
were counterstained with Mayer's hemalum for 5 min.
Restimulation of Primed Antiviral CTL In Vitro CFSE Labeling of Splenocytes
Spleen cells (4 3 106/well) from LCMV-primed mice were restimu- CFSE was purchased from Molecular Probes (Eugene, OR). C57BL/
lated in 24-well tissue culture plates with 2 3 105 irradiated (3000 6 mice were treated intraperitoneally with 500 mg of either LCMV
rad), LCMV-infected macrophages in Iscove's modified Dulbecco's GP33 peptide or VSV NP52 peptide in IFA. Fifteen hours later,
medium supplemented with 10% FCS penicillin/streptomycin and spleens were removed and a single cell suspension was made.
0.001 M 2-mercaptoethanol. Correspondingly, spleen cells (4 3 106/ Erythrocytes were depleted from spleen cell suspension by water
well) from VSV-primed animals were cultivated together with 4 3 lysis. The cells were washed with ice-cold phosphate-buffered sa-
105 irradiated (3000 rad) VSV-NP±transfected N1 cells under the line and resuspended at a concentration of 2 3 107 cells/ml. CFSE
same conditions. After 5 days, restimulated spleen effector cells was kept as a 0.5 mM stock in DMSO and stored at 2208C. Spleno-
from two wells were pooled and resuspended in 1 ml of complete cytes from LCMV GP33 peptide±treated mice were labeled with
minimal essential medium. Serial 3-fold dilutions were made (indi- CFSE at a final concentration of 0.5 mM, and splenocytes of VSV
cated as dilution of culture) and tested in a 51Cr release assay. NP52 peptide±treated mice were labeled at a 10-fold lower concen-
tration (0.05 mM), by incubating them for 10 min at 378C. After label-
Cytotoxicity Assay ing, FCS was added to a final concentration of 5% and cells were
The cytolytic activity of in vitro restimulated virus-specific spleen washed twice with ice-cold phosphate-buffered saline. The two
cells was determined in a 51Cr release assay as described (Zinkerna- splenocyte populations of different CFSE intensities were mixed at
gel et al., 1985). MC57G or EL-4 cells were coated with LCMV pep- a 1:1 ratio, and 6 3 107 cells were adoptively transferred into recipi-
tides GP33 or NP394 or with VSV peptide NP52 at a concentration ent mice.
of 1026 M and were labeled with 250 mCi 51Cr for 2 hr at 378C on a
rocking platform. Target cells were washed three times andcounted. Acknowledgments
Next, 104 target cells were incubated in 96-well round-bottom plates
with a serial 3-fold dilution of restimulated spleen effector cells in Correspondence should be addressed to P. A. This work was sup-
a final volume of 200 ml. After a 5 hr incubation at 378C, 70 ml ported by Swiss National Foundation grants. We thank Lenka Vlk
supernatants were harvested and assayed. Spontaneous release for excellent histology and Norbert Wey and Hannes Nef for photog-
was always less than 20%. Peritoneal macrophages were washed raphy.
twice in balanced salt solution and resuspended in 100 ml of Iscove's
modified Dulbecco's medium supplemented with 10% FCS for 51Cr Received November 8, 1996; revised February 14, 1997.
labeling. Spontaneous release of peritoneal macrophages was be-
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